- Pro Medicus’ US subsidiary, Visage Imaging has signed AUD 14 million deal with University of Vermont that will last for eight years.
- Pro Medicus purchased Visage Imaging in January 2009.
- The deal will see Visage 7 Enterprise Imaging Platform to be introduced across UVM’s six hospitals.
Healthcare informatics company Pro Medicus Limited (ASX:PME) reported on Thursday that Visage Imaging Inc, its wholly-owned U.S. subsidiary, has signed an eight-year contract worth AUD 14 million with The University of Vermont Health Network Inc.
Pro Medicus Limited is a provider of medical imaging software and services to healthcare organisations, hospitals and imaging centres all over the world. The company also provides a leading portfolio of RIS, PACS, Artificial Intelligence (AI), and e-health solutions, making it one of the most extensive end-to-end solutions in the healthcare imaging industry.
Source: © Argus456 | Megapixl.com
What is the Visage 7?
Visage Imaging was purchased by the company in January 2009, transforming it into a multinational supplier of cutting-edge medical imaging solutions. The Visage 7 product suite is the cornerstone of an ultra-fast, scientifically rich, and highly scalable platform that can be used in both public and private cloud environments.
Insight into the deal
The Visage 7 Enterprise Imaging Platform will be implemented across UVM's six hospitals as part of the agreement, providing a single diagnostic imaging platform across the network based on a transactional licencing model. It will be completely implemented in the cloud replacing several legacy PACS.
Pro Medicus Ltd's academic institution presence in the United States will be expanded as a result of the agreement. The company intends to start the launch right away, with initial go-lives scheduled for the second half of the year.
Pro Medicus CEO, Dr Sam Huper said.
Meanwhile, the stock PME ended a tad bit higher at AUD 41.150 per share, up 1.454%, with a market capitalisation at AUD 4.22 billion.
Other companies operating in the same space include Emyria limited (ASX:EMD) that ended 4.445% lower at AUD 0.215, Aroa Biosurgery Limited (ASX:ARX) closed 1.322% down at AUD 1.120, Chimeric Therapeutics Limited (ASX:CHM) ended at AUD 0.260.